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Abstract
Background: Pancreatic cancer ranks as the fourth leading cause of cancer-related mortality in the USA. And
gemcitabine has been the standard of care for advanced pancreatic cancer. However, a combined use of
gemcitabine plus cisplatin (GemCis) has shown promising efficacies in pancreatic cancer patients. Here, system
review and meta-analysis were performed to compare the efficacy and safety of GemCis versus gemcitabine
(Gem) alone in the treatment of pancreatic cancer.
Methods: The databases of MEDLINE (PubMed), EMBASE, and Cochrane Library were systematically searched for
retrieving the relevant publications prior to 31 September 2014. The primary end point was overall survival (OS)
and secondary end points included 6-month survival, 1 year survival, overall response rate (ORR), clinical benefit
rate (CBR), time to progression/progression-free survival (TTP/PFS), and toxicities.
Results: A total of nine randomized controlled trials involving 1354 patients were included for systematic evaluations.
Overall, as compared with Gem alone, GemCis significantly improved the 6-month survival rate (relative risk (RR) = 1.303,
95 % confidence interval (CI) 1.090–1.558, P = 0.004), ORR (RR = 1.482, 95 % CI 1.148–1.913, P = 0.003), PFS/TTP (hazard
ratio (HR) = 0.87; 95 % CI 0.78–0.93, P = 0.022), and the overall toxicities (RR = 2.164, 95 % CI 1.837–2.549, P = 0.000).
However, no significance difference existed in overall survival (HR = 0.90, 95 % CI 0.80–1.42, P = 1.02), 1-year survival
rate (RR = 0.956, 95 % CI 0.770–1.187, P = 0.684), and CBR (RR = 0.854, 95 % CI 0.681–1.072, P = 0.175). As for grade
III/IV toxicity, seven kinds of toxicities were higher in the GemCis group. However, no significant inter-group statistical
differences existed in the incidence of leukopenia, thrombocytopenia, or diarrhea.
Conclusions: Despite a higher incidence of three-fourths toxicity, GemCis offers better outcomes of ORR, PFS/TTP, and
6-month survival, which indicates GemCis may be a promising therapy for pancreatic cancer.
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Background
As the fourth leading cause of cancer-related death in the
USA [1], pancreatic cancer is one of the most lethal malig-
nancies due to its diagnostic difficulties. Most patients
have been in an advanced stage or a metastatic disease
when diagnosed [2]. And 50 % of them were metastatic,
30 % locally advanced, and only 20 % resectable tumors
[3]. Most cases had already progressed beyond the point
of surgical resectability. As reported by the American
Cancer Society, the median survival for locally advanced
pancreatic cancer is only 9–15 months; however, in meta-
static patients, this may fall to 3–6 months and its overall
5-year survival is no more than 4 % [4].
The management modalities of pancreatic cancer
may be summarized as surgical resection, chemother-
apy, radiotherapy, chemoradiation, etc. Despite an
availability of different managements, the outcomes of
pancreatic cancer patients were similar with a median
survival of 20 to 22 months [5]. So improving disease
symptoms and quality of life and offering better clin-
ical benefits have become the key end points of pallia-
tive chemotherapies [6].
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In 1997, gemcitabine (Gem) became a de facto stand-
ard of care for advanced pancreatic cancer. As com-
pared to 5-fluorouracil, it modestly increased overall
survival and offers better clinical benefits [7]. Gemcita-
bine has consistently resulted in a median overall sur-
vival of 5–7 months and approximately 20 % increase in
1-year survival rate in metastatic patients [8]. Though with
a modest clinical benefit, it failed to improve much of the
dismal prognosis. For achieving better clinical efficacies,
multiple gemcitabine-based schemes have been attempted
in clinical setting.
As a valid inducer of apoptosis in pancreatic cancer
cells, cisplatin is among the most effective and widely
used chemotherapeutic agents [9]. A combination of
gemcitabine plus cisplatin (GemCis) was synergistic so
that it worsened DNA damage [10, 11].
A previous meta-analysis presented by Xie et al. [12]
in 2006 suggested that the gemcitabine monotherapy
has remained as a standard treatment for pancreatic
cancer, while the combination regimen is not recom-
mended. Their meta-analysis has included some meet-
ing abstracts whose full texts could not be acquired, so
that their conclusion is somewhat weak. And the search
was restricted up to March 2005. For updating and
strengthening, the authors performed another meta-
analysis of recently published trials comparing GemCis
with Gem alone with regards to median OS, 6-month
and 1-year survivals, overall response rate (ORR), and
clinical benefit rate (CBR).
Methods
Searching strategy
From inception to 31 September 2014, comprehensive
electronic searches were performed within the data-
base of EMBASE, MEDLINE (PubMed), Cochrane
Central Register of Controlled Trials, China National
Knowledge Infrastructure (CNKI). The relevant medical
subject heading and free words included “gemcitabine,”
“gemzar,” “cisplatin,” and “pancreatic cancer/carcinoma/
adenocarcinoma.” And the searching languages were lim-
ited to English and Chinese.
Date extraction and quality assessment
Two authors (i.e., GQOY and ZPL) independently ab-
stracted the data from each study. Any discrepancies be-
tween the two reviewers were resolved by consensus and
discussion. The following parameters were extracted: (1)
publication and first author’s name; (2) patients, character-
istics, number of eligible patients, treatment arm, study
design, and follow-ups; (3) treatment outcome, such as
OS, 6-month and 1-year survival rates, ORR, CBR, TTP/
PFS, and toxicities.
Criteria for inclusion and exclusion
The studies included in this meta-analysis should fulfill
the following inclusion criteria: (1) cytologically or histo-
logically confirmed advanced stage and/or metastatic
pancreatic cancer; (2) baseline Karnofsky performance
status score ≥50 % (or ECOG performance status <2)
and adequate renal, hematological, hepatic, and cardiac
functions; (3) aged over 18 years; and (4) without anti-
tumor therapy within 6 months before study. And the
exclusion criteria were studies without a full text and
non-published conference abstracts. For duplicated lit-
erature reports, the most comprehensive ones were se-
lected. Also, other reports might be supplemented.
Statistical analysis
All analyses were performed strictly with Stata version
12.0 software (Stata Corporation, College Station, Texas,
USA). The primary end points included OS. Six-month
and 1-year survival rates, ORR, CBR, TTP/PFS, and tox-
icities were used as second end points. Relative risk (RR)
was calculated with a method for dichotomous data and
weighted mean difference (WMD) for continuous out-
comes and pooled across studies using the DerSimonian
and Laird random effects model [13]. The hazard ratios
(HRs) with 95 % confidence intervals (CIs) were esti-
mated directly or indirectly from the reported data. And
the OS and PFS were measured by HR in this study. The
χ2-based Q-test and I2 statistics were used to assess het-
erogeneity of studies. If there were statistical differences
in terms of heterogeneity (I2 > 50 %, p < 0.10), a random
effects model was selected; otherwise, a fixed effects
model was used. Forest plots for each meta-analysis were
used to present the raw data (means, SDs, and sample
sizes) for each arm of the study potential. Publication
biases were ascertained by visually inspecting funnel plots
for ORR analysis. The relative symmetry of individual
study estimates was assessed around overall estimate,
followed by Begg’s and Egger’s tests.
Results
Literature search
A total of 424 potentially relevant publications were
identified by initial electronic searches. After duplicating
and reviewing the full texts, only nine articles [2, 14–21]
were eligible for this meta-analysis (Fig. 1). A total of
eight randomized controlled trials and one retrospective
study compared GemCis with Gem alone in advanced
and metastatic pancreatic cancers were enrolled in this
study.
The basic characteristics of included studies are sum-
marized in Table 1. A total of 1354 patients from nine
articles were analyzed. Among them, 725 patients were
allocated to the GemCis group and 629 patients in the
Gem-alone group. Their median ages were similar at
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around 45 to 69 years old. And the gender ratios of
GemCis and Gem alone were 473/253 and 391/258, re-
spectively. No gender differences existed between trials
according to patient characteristics. The values of ORR
were extracted from each of the eight trials and 1-year
survival rates from seven trials. Only a few trials pro-
vided the values of OS, 6-month survival, and CBR.
Overall survival
Eight studies reported the median overall survival, ranging
from 4.8 to 22 months. The HRs of OS were calculated or
acquired from five studies. After pooling the data, no het-
erogeneity among the studies (I2 = 0, P = 0.926) was found;
therefore, a fixed model was employed for meta-analysis
of HR. The overall meta-analysis revealed that HR was
lower for the patients treated with GemCis than with
Gem alone. However, no difference was found between
the two groups (HR = 0.90, 95 % CI 0.80–1.42, P = 0.10)
(Fig. 2).
Six-month and 1-year survival rates
The relevant 6-month survival data were reported for
five trials. And a total of 428 patients from these five
trials, 213 from the GemCis group and 215 in the
Gem-alone group, were included into this meta-analysis.
The results showed a general trend of higher 6-month
survival rate in the GemCis group than in the Gem-alone
group (RR = 1.303, 95 % CI 1.09–1.56, P = 0.004). And a
small significant heterogeneity existed (I2 = 42.5 %, P =
0.138) (Fig. 3).
Eight hundred twenty-six patients from six randomized
controlled trials reported the 1-year survival data. There
Fig. 1 Flowchart of the search strategy





Patients Median age (range) Male/female Jade score
GemCis Gem GemCis Gem GemCis Gem Gem
Colucci 2002 Phase 3 NA 107 53 54 60 (33–71) 63 (43–75) 35:18 27:27 3
Wang 2002 RCT July 2000 to May 2001 42 22 20 65 (37–76) 57 (35–60) 15:7 14:6 NA
Heinemann 2006 Phase 3 December 1997 to January 2002 190 95 95 66 (37–82) 66 (43–85) 63:33 59:36 4
H. Palmer 2007 Phase 2 November 1999 to May 2003 50 26 24 66 (47–78) 66 (40–79) 13:13 13:11 3
Sun 2007 RCT January 2003 to February 2006 53 27 26 55 58 17:10 15:11 3
Colucci 2010 Phase 3 April 2004 to April 2007 400 201 199 63 (37–75) 63 (37–75) 125:76 133:86 4
Inal 2012 Retrospective
patient series
September 2006 to March 2011 406 250 156 57 63 175:75 98:58 0
Liu 2012 RCT May 2005 to July 2008 60 30 30 48 (23–74) 45 (20–69) 13:17 14:16 3
Chao 2013 RCT February 2000 to December 2002 46 21 25 69 (47–81) 69 (46–83) 17:4 18:7 3
NA not available
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was no statistically significant inter-group difference that
existed in the 1-year survival rate (RR = 0.96, 95 % CI
0.77–1.19, P = 0.68). However, no significant inter-
group heterogeneity existed in the 1-year survival rate
(I2 = 0.0 %, P = 0.559) (Fig. 4).
Overall response rate
Eight eligible studies reported the values of ORR. The
result of the test for heterogeneity of the therapeutic ef-
fect was not significant (I2 = 5.2 %, P = 0.390). So, a fixed
effects model was employed. Significant differences
existed between GemCis and Gem-alone groups. And
the meta-analysis revealed that the combination group
was linked with higher ORR than the Gem-alone group
(RR = 1.48, 95 % CI 1.15–1.91, P = 0.003) (Fig. 5).
Clinical benefit rate
CBR was reported for five studies involving a total of
578 patients. There were no significant differences that
existed between the GemCis and Gem-alone group (RR
= 0.85, 95 % CI 0.68–1.07, P = 0.175). And small hetero-
geneity was seen between the two groups regarding the
outcome of CBR (I2 = 18.8 %, P = 0.295) (Fig. 6).
Time to progression/progression-free survival
PFS was defined as the time from random assignment until
death or an evidence of tumor progression [19]. And TTP
denoted the time from the date of an initial dose of study
drug to the observation date of initial disease. In most
cases, PFS was rather close to TTP; therefore, the values of
TTP and PFS could be co-analyzed [22].
Fig. 2 Overall survival between patients treated with GemCis versus Gem
Fig. 3 Six-month survival rate between patients treated with GemCis versus Gem
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Five trials reported the values of TTP/PFS. And 749
patients from the five studies were divided into two
groups of GemCis (n = 419) and Gem alone (n = 330).
Overall, there was a significant increase in the TTP/PFS
when the GemCis is compared with the Gem group
(HR = 0.87, 95 % CI 0.78–0.98, P = 0.022). And the
heterogeneity between the two groups regarding the out-
come of TTP/PFS was low (I2 = 23.1 %, P = 0.267)
(Fig. 7).
Toxicity
The grade III/IV toxic effects of chemoradiotherapy
were summarized in the table. As shown in Table 2,
neutropenia (18.4 %) was the most common toxicity of
the two arms. And the incidence of the other six toxic-
ities was under 10.0 %. After data pooling, there was no
evidence of heterogeneity except for thrombocytopenia
and diarrhea while the I2 of diarrhea was 43 % and
that of thrombocytopenia was 70.7 %, respectively
(Table 2). So, six toxic events used fixed model except
thrombocytopenia. As shown in Table 2, as compared
with Gem alone, GemCis significantly increased the
incidence of neutropenia, anemia, nausea, and vomit-
ing, while showing no difference in the incidence of
leukopenia, thrombocytopenia, and diarrhea between
the two groups, but GemCis shows a high incidence
compared with Gem (Table 2). After data pooling of
the seven toxicities, we found that GemCis acquired
higher toxicity that Gem alone (RR = 2.164, 95 % CI
1.837–2.549, P = 0.000).
Publication bias
Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias of the selected studies for ORR
Fig. 4 One-year survival rate between patients treated with GemCis versus Gem
Fig. 5 Overall response rate between patients treated with GemCis versus Gem
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analysis. The shape of the funnel plots did not show
obvious evidence of asymmetry (P = 0.71 for ORR, see
Fig. 8). The Egger’s test did not show any significant
publication bias (P = 0.39 for ORR).
Discussion
Pancreatic cancer is one of the deadliest cancers, with an
overall 5-year survival rate of no more than 5 % [23, 24].
Owing to several factors, rapid proliferation of pancre-
atic cancer cells, aggressive local invasion, metastasis,
high local recurrence rate, and resistance to most forms
of treatment, the prognosis of pancreatic cancer is still
poor [25]. The early stage of pancreatic cancer is usually
clinically silent, and we can detect the disease only after
it invaded the surrounding tissues or metastasizes to a
distant organ [4]. So, most of the patients with pancre-
atic cancer often lost the opportunity to be resected
when diagnosed. Therefore, palliative chemotherapy
becomes an option for those patients. However, over
the last decades, the treatment of gemcitabine had
achieved some great success. In 1997, it was reported
that single-agent gemcitabine yielded higher rates of CBR
and survival [7]. Afterward gemcitabine has become a
mainstay treatment for metastatic pancreatic cancer [25].
Recently, the Gem-based combination therapy was more
recommended, due to the limited survival benefit of Gem
monopoly. According to the published meta-analysis,
Gem-based combination therapy significantly improved
OS. However, the advantage was limited due to a higher
toxicity. It was suggested that the prescription of Gem-
based combination regimens should be selected [26].
Another meta-analysis revealed that polychemotherapy
significantly improved OS, PFS, and response rate com-
pared with Gem alone [6]. Cisplatin is a well-known anti-
cancer drug, and it is one of the most effective and widely
used chemotherapeutic drugs for the treatment of several
Fig. 6 Clinical benefit rate between patients treated with GemCis versus Gem
Fig. 7 TTP/PFS between patients treated with GemCis versus Gem
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types of solid tumors, particularly testicular or ovarian
cancer patients [27]. Whether GemCis can achieve a bet-
ter benefit than Gem alone is debated.
In the present meta-analysis, we examined the thera-
peutic efficacy and safety of Gem-plus-cisplatin-based
versus Gem alone for pancreatic cancer. Several clin-
ical studies suggested that a combined use of GemCis
was feasible, and it could improve ORR, PFS, and OS
[8, 19–22]. According to the included articles in our
meta-analysis, the median OS of patients treated by
GemCis ranged from 5.5 to 22 months. After pooling
the data, it appeared that GemCis may lower the HR
for OS than Gem alone; however, no difference was
found and and the heterogeneity was existed (I2 = 0, P
= 0.926); the heterogeneity that was not found may re-
sult from the same chemotherapy medicine. The TTP/
PFS reported by the existing studies varied from 3.6 to
10.4 months in GemCis regimen and from 2.0 to
12.2 months in Gem. The pooled HR for TTP/PFS
performed by our analysis was 0.87, indicating a 13 %
reduction in the risk of death in patients treated with
GemCis regimen. The results were also consistent
with those of Heinemann’s study. Comparing GemCis
with Gem alone, OS and PFS/TTP of GemCis were
both superior to those of Gem alone [19]. Yet, abso-
lute improvements of OS and PFS/TTP were marginal.
For the 6-month survival rate, GemCis achieved a sta-
tistically significant improvement for Gem alone and
GemCis had a higher 6-month survival rate of 30 %
than Gem monopoly. It was suggested that the com-
bination group could prolong short-term survival rate.
Nevertheless, no significant inter-group difference
existed in the 1-year survival rate. The short-term 6-
month survival rate was consistent with that of Banu et al.
[28]. However, the difference in the 1-year survival of two
studies might be due to the fact that the combination
group of the Banu study contained different drugs. Based
upon the above results, GemCis might achieve better out-
comes in short-term survival. However, the long-term sur-
vival remained inconclusive. Thus, Gem plus cisplatin is
recommended over Gem alone.
In the present study, GemCis significantly increase ORR
by 48.2 % as compared with Gem alone. Two recent
meta-analyses of Gem-plus-fluorouracil versus Gem alone
Table 2 Toxicity of GemCis and Gem
Toxicity GemCis n/N Gem n/N RR 95 % CI I2 P
Leukopenia 29/603 20/518 1.496 0.865–2.586 0 0.801
Neutropenia 124/529 52/442 2.02 1.493–2.732 0 0.734
Thrombocytopenia 68/552 28/465 1.871 0.724–4.831 70.70 % 0.017
Anemia 72/624 29/537 2.022 1.336–3.060 0 0.591
Nausea 80/624 25/537 2.492 1.629–3.811 0 0.892
Vomiting 59/552 15/465 3.051 1.773–5.253 0 0.773
Diarrhea 32/603 13/518 1.82 0.961–3.446 43 % 0.153
RR relative ratios, CI confidence interval
Fig. 8 Begg’s funnel plot of publication bias test
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indicated that the combination group significantly im-
proved the outcome of ORR [29, 30]. And it was sug-
gested that cisplatin or fluorouracil-plus-Gem might
achieve synergistic effects. Another meta-analysis also
revealed that Gem-based combination increased 51 %
of ORR than single-agent Gem; moreover, combina-
tions of Gem-plus-platinum salts improved ORR by
77 % as compared with Gem alone [31]. CBR was re-
ported in five of nine studies, and it was lower in the
combination group than in Gem-alone group reported
in two studies [16, 17]. However, three other articles
were on the contrary [14, 15, 18]. Our meta-analysis re-
vealed no significant difference in CBR between Gem-
Cis and Gem. One of the most important reasons is
that CBR was appraised by pain, functional impairment,
and weight loss [17, 18]. However, toxicity and subject-
ive feeling might also play some contributory roles.
In our meta-analysis, we found that GemCis was associ-
ated with high incidence of adverse events. Pooled toxicity
data significantly increased by 116 % in GemCis versus
Gem alone (RR = 2.164, 95 % CI 1.837–2.549, P = 0.000).
This result was in accordance with another meta-analysis
comparing Gem-plus-fluorouracil versus Gem alone [29].
Although the present meta-analysis demonstrated a statis-
tically significantly greater incidence of grades III/IV neu-
tropenia, anemia, nausea, and vomiting in the GemCis
group, the PFS, 6-month survival, and ORR, however,
significantly increased may make the toxicity generally
tolerable and reversible. In our study, some toxicities were
excluded for meta-analysis (e.g., mucositis, platelets, and
fever) due to the different schemes for safety assessment.
Thus, more studies are required for further clarifications.
Some limitations of the present meta-analysis should be
acknowledged. Firstly, this meta-analysis only drew upon
published data rather than individual patient profiles. Sec-
ondly, the sample size was too small to have a sufficient
statistical power for the efficiency and safety of pancreatic
cancer between GemCis and Gem. Therefore, more stud-
ies with larger sample sizes are needed. Third, different
doses of cisplatin yielded divergent outcomes.
Conclusions
The present study meta-analysis revealed a significant
improvement in the 6-month survival rate, PFS/TTP,
and ORR of pancreatic cancer. However, no significant
difference existed in OS, 1-year survival, and CBR. The
incidence of grade III/IV toxicity was higher for GemCis
than for Gem alone. Yet, the incidence of adverse events
for GemCis remained generally tolerable. In conclusion, a
combined use of Gem and cisplatin is superior to Gem
alone as an alternative chemotherapy for pancreatic cancer.
However, owing to the above limitations, more convincing
studies are warranted.
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